Behavioral Intervention
Mindfulness and CBT for Preventing Severe Mental Illness in Youth
This trial will test a new intervention to prevent severe mental illness in young people who are at high risk. The intervention will target early preceding factors to severe mental illness, which are often impairing and distressing to the individual but can be improved with self-management skills and parent training. The goal is to intervene early enough in the young person's life that severe mental illness can be prevented.
Behavioral Intervention
Cognitive Behavioral Therapy for Serious Mental Illness-related Chronic Pain
This trial is testing whether a therapy called CBT-CP, which is used to help manage chronic pain, is feasible and acceptable to Veterans with SMI, and if it is worth examining in a larger clinical trial.
Popular Filters
Trials for Schizoaffective Disorder Patients
Bromocriptine for Schizophrenia and Diabetes-Related Issues
This trial is testing whether bromocriptine, a drug that affects dopamine and serotonin levels, is a safe and tolerable way to improve glucose tolerance and insulin resistance in people with schizophrenia who are also taking antipsychotic drugs.
Behavioural Intervention
Visual Perceptual Remediation for Schizophrenia
This trial will evaluate the effectiveness of different interventions targeting visual functions that are often impaired in people with schizophrenia. The study will compare the effects of the interventions to a control condition of higher-level cognitive remediation. Outcome measures include multiple aspects of visual functioning, as well as visual cognition and overall community functioning.
Trials for First Episode Psychosis Patients
Bromocriptine for Schizophrenia and Diabetes-Related Issues
This trial is testing whether bromocriptine, a drug that affects dopamine and serotonin levels, is a safe and tolerable way to improve glucose tolerance and insulin resistance in people with schizophrenia who are also taking antipsychotic drugs.
Diet and Exercise for Schizophrenia
This trial will study how drugs for schizophrenia can lead to weight gain, and how diet and exercise may help. They will look at how people's brains react to food, and ask about eating habits and symptoms. Some participants may do an exercise or diet intervention.
Phase 3 Trials
Atypical Antipsychotic
Cariprazine for Pediatric Schizophrenia
This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.
Atypical Antipsychotic
OLZ/SAM for Schizophrenia
This trial evaluates the safety and tolerability of OLZ/SAM in children and adolescents with schizophrenia or Bipolar I disorder. OLZ/SAM combines olanzapine to manage symptoms and samidorphan to reduce weight gain. Olanzapine is a well-established antipsychotic effective for schizophrenia and bipolar I disorder, but its use is limited by significant weight gain; samidorphan is added to mitigate this side effect.
Medication
Long-term Safety of Iclepertin for Schizophrenia
This trial is for people with schizophrenia who have taken part in previous studies. The purpose is to see if they can tolerate a medicine called BI 425809 in the long term. They take it once a day for a year, plus their normal medication. They have 13 visits and 9 phone calls with the study team.
Trials With No Placebo
Bromocriptine for Schizophrenia and Diabetes-Related Issues
This trial is testing whether bromocriptine, a drug that affects dopamine and serotonin levels, is a safe and tolerable way to improve glucose tolerance and insulin resistance in people with schizophrenia who are also taking antipsychotic drugs.
Behavioural Intervention
Visual Perceptual Remediation for Schizophrenia
This trial will evaluate the effectiveness of different interventions targeting visual functions that are often impaired in people with schizophrenia. The study will compare the effects of the interventions to a control condition of higher-level cognitive remediation. Outcome measures include multiple aspects of visual functioning, as well as visual cognition and overall community functioning.
View More Related Trials
Frequently Asked Questions
Introduction to schizophrenia
What are the top hospitals conducting schizophrenia research?
When it comes to advancing the understanding and treatment of schizophrenia, several top hospitals are leading the way with their groundbreaking clinical trials. In Toronto, the Centre for Addiction and Mental health is at the forefront with five active trials focused on this complex condition. With a remarkable history of 48 completed studies since their first recorded schizophrenia trial in 1999, this institution has been dedicated to making strides in mental health research. Meanwhile, over in Atlanta, the Atlanta Center for Medical Research is actively conducting four trials targeting schizophrenia. Their commitment to advancing knowledge about this disorder can be traced back to their initial trial in 2002.
In DeSoto, Texas, the Neurocrine Clinical Site has recently emerged as an important player in addressing schizophrenia through clinical trials. Although they have only conducted four trials thus far since recording their first one in 2021, their dedication holds great promise for future breakthroughs.
Heading across international borders to Berlin brings us to Hassman Research Institute. This esteemed hospital boasts four ongoing clinical trials exploring various aspects of schizophrenia while having achieved significant progress through twenty-seven previous investigations since starting their pioneering work in 2015.
Last but not least, we turn our attention to Pittsburgh's University of Pittsburgh where three active clinical trials are currently underway focusing on unraveling the mysteries surrounding schizophrenia. Since initiating research efforts back in 2001 with their very first recorded trial on this subject matter; they have completed eleven additional studies that have contributed valuable insights into this condition.
These prominent hospitals serve as beacons of hope for those affected by schizophrenia and demonstrate unwavering dedication towards improving outcomes and quality of life for individuals living with this challenging disorder worldwide.
Which are the best cities for schizophrenia clinical trials?
When it comes to schizophrenia clinical trials, several cities emerge as leading hubs for research and development. Atlanta, Georgia boasts 17 active trials focused on investigating treatments like SEP-363856, Xanomeline and Trospium Chloride Capsules, and Infliximab. New york City follows closely behind with 12 ongoing studies exploring interventions such as Clozapine, Brain Basics, and Motivation Skills Training (MST). San Diego, California also stands out with 10 active trials examining potential advancements like SEP-363856 and Xanomeline and Trospium Chloride Capsules. With their commitment to innovative research efforts in the field of schizophrenia treatment, these cities offer hope for improved outcomes for individuals living with this condition.
Which are the top treatments for schizophrenia being explored in clinical trials?
The field of schizophrenia research is rapidly advancing, with several promising treatments being explored in clinical trials. Leading the way is SEP-363856, currently involved in five active trials and boasting a total of 17 all-time studies dedicated to schizophrenia since its listing in 2013. Another noteworthy contender is valbenazine, which has shown promise in three ongoing trials and was first listed just this year (2021). Additionally, transcranial direct current stimulation and cognitive enhancement therapy are both being investigated through multiple active trials, offering new avenues for potential treatment options. Lastly, OLZ/SAM shows potential with two active trials despite its recent introduction in 2021. These exciting developments hold the promise of improved outcomes for individuals living with schizophrenia.
What are the most recent clinical trials for schizophrenia?
Exciting advancements are underway in the field of schizophrenia treatment, as recent clinical trials offer promising possibilities for patients. One such trial investigates the effectiveness of infliximab in managing symptoms and improving overall well-being among individuals with schizophrenia. Another study explores a combination therapy consisting of dasatinib and quercetin, aiming to target specific molecular pathways implicated in the disorder. Additionally, MK-8189 is being evaluated for its potential therapeutic benefits in treating schizophrenia, while SEP-363856 holds promise as a novel compound that may provide relief from psychotic symptoms. Lastly, valbenazine is currently undergoing phase 4 trials to assess its efficacy and safety profile for use in managing schizophrenia symptoms. These exciting developments bring hope and new avenues for those affected by this complex condition.
What schizophrenia clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of schizophrenia treatment. In July 2022, Merck Sharp & Dohme LLC successfully completed a trial evaluating the potential of MK-8189 for this complex mental disorder. Earlier, in April 2022, another breakthrough was achieved with the completion of a trial testing Nicotine patch as a therapeutic option, sponsored by Merck Sharp & Dohme Corp. Furthermore, Cerevel Therapeutics LLC concluded their CVL-231 study in January 2022 and also finished a separate trial involving CVL-231 Target Release (Fasted) in December 2021. These advances highlight ongoing efforts to address the challenges faced by individuals living with schizophrenia and offer hope for improved treatment options.